Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The importance ofFLT3mutational analysis in acute myeloid leukemia
Mrinal M. Patnaik
Leukemia & lymphoma/Leukemia and lymphoma (2017) Vol. 59, Iss. 10, pp. 2273-2286
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver, Richard F. Schlenk, Nigel H. Russell, et al.
Leukemia (2019) Vol. 33, Iss. 2, pp. 299-312
Open Access | Times Cited: 814
Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies
Yuxian Huang, Yinjie Qin, Ying-Zhi He, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101082-101082
Open Access | Times Cited: 15
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
Martina Ruglioni, Stefania Crucitta, Giovanna Irene Luculli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104424-104424
Open Access | Times Cited: 13
Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia
Qi Zhou, Yongyu Guan, Pingping Zhao, et al.
Translational Oncology (2025) Vol. 52, pp. 102271-102271
Closed Access | Times Cited: 1
Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells
Tatsuya Kawase, Taisuke Nakazawa, Tomohiro Eguchi, et al.
Oncotarget (2019) Vol. 10, Iss. 58, pp. 6111-6123
Open Access | Times Cited: 61
Role of Biomarkers in FLT3 AML
Nitika Nitika, Jiao Wei, Ai‐Min Hui
Cancers (2022) Vol. 14, Iss. 5, pp. 1164-1164
Open Access | Times Cited: 33
Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML
Diana Macečková, Lenka Vaňková, Monika Holubová, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 7
Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design
Almudena Aguilera-Diaz, Iria Vázquez, Beñat Ariceta, et al.
PLoS ONE (2020) Vol. 15, Iss. 1, pp. e0227986-e0227986
Open Access | Times Cited: 42
A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’
Alexandre Bazinet, Sarit Assouline
Expert Review of Hematology (2021) Vol. 14, Iss. 2, pp. 185-197
Closed Access | Times Cited: 36
Moving toward individualized target-based therapies in acute myeloid leukemia
Alexandre Bazinet, Hagop M. Kantarjian
Annals of Oncology (2022) Vol. 34, Iss. 2, pp. 141-151
Open Access | Times Cited: 28
Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline
Valérie de Haas, Nofisat Ismaila, Anjali S. Advani, et al.
Journal of Clinical Oncology (2018) Vol. 37, Iss. 3, pp. 239-253
Open Access | Times Cited: 42
Targeted chemotherapy overcomes drug resistance in melanoma
Jingyin Yue, Roberto Vendramin, Fan Liu, et al.
Genes & Development (2020) Vol. 34, Iss. 9-10, pp. 637-649
Open Access | Times Cited: 33
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
Melisa Tecik, Aysun Adan
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1449-1478
Open Access | Times Cited: 22
The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias
Robert Roskoski
Pharmacological Research (2020) Vol. 155, pp. 104725-104725
Closed Access | Times Cited: 28
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
Salvatore Perrone, Tiziana Ottone, Nadezda Zhdanovskaya, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 2, pp. 223-38
Open Access | Times Cited: 10
Comparison of autologous hematopoietic cell transplantation, matched sibling donor hematopoietic cell transplantation, and chemotherapy in patients with favorable- and intermediate-risk acute myeloid leukemia
Mingyang Wang, Shulian Chen, Qiuqiu Zhang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Synthesis and Anti-acute Myeloid Leukemia Activity of Cyclopropane-1,1-diamide Derivatives Containing Imidazo[1,2-a]pyridine
L. Eduardo Wu, Jiangdong Li, Zhonghua Shi, et al.
Chinese Journal of Organic Chemistry (2025) Vol. 45, Iss. 1, pp. 286-286
Closed Access
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia
Alexandre Bazinet, Álex Bataller, Tapan M. Kadia, et al.
Cancer (2025) Vol. 131, Iss. 6
Closed Access
Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation
Fang Chen, Junya Sun, Changxin Yin, et al.
Bone Marrow Transplantation (2019) Vol. 55, Iss. 4, pp. 740-748
Open Access | Times Cited: 29
Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios
Kun‐yin Qiu, Xiong‐yu Liao, Yong Liu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
Melisa Tecik, Aysun Adan
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 6, pp. 719-751
Open Access | Times Cited: 3
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Tamara Castaño-Bonilla, Juan Manuel Alonso‐Domínguez, Eva Barragán, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 17
Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation–positive acute myeloid leukemia: the RADIUS-X expanded access program
Gail J. Roboz, Stephen A. Strickland, Mark R. Litzow, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2020) Vol. 61, Iss. 13, pp. 3146-3153
Open Access | Times Cited: 18
Profiling FLT3 Mutations in Mexican Acute Myeloid Leukemia Pediatric Patients: Impact on Overall Survival
Carolina Molina Garay, Karol Carrillo Sánchez, Luis Leonardo Flores Lagunes, et al.
Frontiers in Pediatrics (2020) Vol. 8
Open Access | Times Cited: 17
How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
Tobias R. Haage, Burkhart Schraven, Dimitrios Mougiakakos, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2991-2991
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top